• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Gaxos.ai Inc.

    2/4/26 5:11:57 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology
    Get the next $GXAI alert in real time by email
    424B5 1 ea0275510-424b5_gaxos.htm PROSPECTUS SUPPLEMENT

    Filed Pursuant to Rule 424(b)(5)

    Registration No. 333-283758

     

    PROSPECTUS SUPPLEMENT

    (To Prospectus dated December 18, 2024

    To Prospectus Supplement dated January 23, 2026)

     

    Up to $2,600,000

    Common Stock

     

     

     

    Gaxos.ai Inc.

     

    This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus, dated December 18, 2024, filed as a part of our registration statement on Form S-3 (File No. 333-283758), as supplemented by our prospectus supplement dated January 23, 2026 (collectively, the “Prior Prospectus”). This prospectus supplement should be read in conjunction with the Prior Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prior Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prior Prospectus, and any future amendments or supplements thereto.

     

    We filed the Prior Prospectus to register the offer and sale of our common stock, par value $0.0001 per share, from time to time pursuant to the terms of that certain At The Market Offering Agreement, dated January 23, 2026 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC, (the “Sales Agent” or “Wainwright”), acting as the agent, and us.

     

    Since our entry into the Sales Agreement, we have offered and sold 1,515,700 shares of common stock for gross proceeds of approximately $3,000,000 million pursuant to the Sales Agreement.

     

    We are filing this Prospectus Supplement to supplement the Prior Prospectus to increase the aggregate amount we intend to sell pursuant to the Sales Agreement. As of the date of this Prospectus Supplement, we are offering up to an additional aggregate of $2,600,000 of our common stock for sale under the Sales Agreement, not including the shares of common stock previously sold pursuant to the Sales Agreement.

     

    Our common stock is listed on the Nasdaq Capital Market under the symbol “GXAI.” On February 3, 2026, the last reported sale price of our common stock was $2.00 per share.

     

    As of the date of this prospectus supplement, the aggregate market value of our common stock held by non-affiliates of our public float was approximately $16,833,442 based on a total number of 8,639,153 shares of common stock outstanding, of which 8,416,721 shares of common stock were held by non-affiliates, at a price of $2.00 per share, the closing sales price of our common stock on February 3, 2026, which is the highest closing price of our common stock on Nasdaq Capital Market within the prior 60 days. We have sold approximately $3,000,000 of securities pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date of this prospectus supplement (excluding this offering). Accordingly, based on the foregoing, we are currently eligible under General Instruction I.B.6 of Form S-3 to offer and sell shares of our Common Stock having an aggregate offering price of up to approximately $2,611,395. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding one-third of our public float in any 12-month period so long as our public float remains below $75.0 million.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

     

    H.C. Wainwright & Co.

     

    The date of this prospectus supplement is February 4, 2026

     

     

    Get the next $GXAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GXAI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GXAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Amazon AWS Funds Gaxos AI Sales Platform Development

    Caylent Named Development Partner to Lead AWS-Native Build Roseland, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced that Amazon Web Services ("AWS") has committed to fund the preliminary development of Gaxos Labs' innovative, AI-powered sales coaching platform, positioning Gaxos to compete in the multibillion- dollar sales technology market. The AWS-backed initiative, in collaboration with Caylent, an AWS premier partner, supports the development of a real-time, AI sales platform designed for enterprise-scale deployment, incorporating live call t

    2/3/26 8:12:00 AM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    Gaxos Enters Multibillion-Dollar Digital Faith Market with Launch of Bible Pray AI

    Roseland, NJ, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced the official launch of Bible Pray AI, a personalized, AI-powered spiritual growth platform designed to help users deepen faith, strengthen daily devotion, and apply scripture for greater peace, clarity, and purpose. Bible Pray AI represents Gaxos' strategic expansion into the rapidly growing digital faith, mental wellness, and personal development economy, a sector supported by hundreds of millions of engaged global users seeking guided spiritual content, daily motivation, and community-base

    12/9/25 8:00:00 AM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    Gaxos to Participate in Upcoming WAWTech Conference on December 16th and 17th in Warsaw, Poland

    Roseland, NJ, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced its participation in the upcoming WAWTech Conference, taking place on December 16-17, 2025 in Warsaw, Poland. "We're thrilled to take part in this year's WAWTech Conference ," said Vadim Mats, CEO of Gaxos. "This event offers a tremendous opportunity to engage with technology leaders and innovators across Europe, exchange ideas, and build partnerships that accelerate the growth and adoption of Gaxos AI offerings." To meet with Gaxos at the conferences or for press inquiries, please email pre

    11/12/25 8:00:00 AM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    $GXAI
    SEC Filings

    View All

    Gaxos.ai Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - GAXOS.AI INC. (0001895618) (Filer)

    2/4/26 5:14:56 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 424B5 filed by Gaxos.ai Inc.

    424B5 - GAXOS.AI INC. (0001895618) (Filer)

    2/4/26 5:11:57 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 424B5 filed by Gaxos.ai Inc.

    424B5 - GAXOS.AI INC. (0001895618) (Filer)

    1/23/26 4:35:48 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    $GXAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Holzer Adam

    4 - GAXOS.AI INC. (0001895618) (Issuer)

    4/15/25 7:03:36 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Director Grayson Scott

    4 - GAXOS.AI INC. (0001895618) (Issuer)

    4/15/25 7:02:46 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Director Feldman Roman

    4 - GAXOS.AI INC. (0001895618) (Issuer)

    4/15/25 7:01:32 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    $GXAI
    Leadership Updates

    Live Leadership Updates

    View All

    Gaxos Health Expands Medical Advisory Board

    Roseland, NJ, April 25, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that Gaxos Health has expanded its Medical Advisory Board with the appointment of Dr. Eric Margolis and Dr. Jeff Pavell. "The addition of top medical talent to our Medical Advisory Board reflects our continued commitment to pursuing a best-in-class solution for Gaxos Health," said Vadim Mats, CEO of Gaxos.AI. "An advisory board of experts in their respective fields will allow to create a better product and advancing our mission of creating value for shareholders." Dr. Eric Margolis, M.D.  is a Board-Ce

    4/25/24 8:45:00 AM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    $GXAI
    Financials

    Live finance-specific insights

    View All

    Gaxos Acquires Rights to AI-enabled Technology from Top Biohacking App

    Roseland, NJ, March 13, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that it had acquired the rights to use certain AI-enabled technology from a top biohacking app, "Ultiself," in order to facilitate the development of its tech for Gaxos Health. The integration of Ultiself's proprietary technology into Gaxos Health's proposed product offering will enable enhanced customization and user experience aligning with modern-day consumer's demands for custom and efficient solutions. This move is expected to accelerate Gaxos Health's development and help solidify its positio

    3/13/24 8:30:00 AM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology

    $GXAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Gaxos.ai Inc.

    SC 13G - GAXOS.AI INC. (0001895618) (Subject)

    11/14/24 3:30:50 PM ET
    $GXAI
    Computer Software: Prepackaged Software
    Technology